As of June 14, 2025, Endonovo Therapeutics Inc (ENDV) reports a Gross Margin of 92.62%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Endonovo Therapeutics Inc's Gross Margin
Over recent years, Endonovo Therapeutics Inc's Gross Margin has shown significant volatility. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2022-12-31 | 92.62% |
| 2021-12-31 | 79.50% |
| 2020-12-31 | 60.57% |
| 2019-12-31 | 69.89% |
| 2018-12-31 | 84.47% |
This slight upward trend highlights how Endonovo Therapeutics Inc manages its operational efficiency and pricing power over time.
Comparing Endonovo Therapeutics Inc's Gross Margin to Peers
To better understand Endonovo Therapeutics Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Endonovo Therapeutics Inc (ENDV) | 92.62% |
| Arno Therapeutics Inc (ARNI) | 7775.20% |
| Karuna Therapeutics Inc (KRTX) | 7775.20% |
| Baseline Productions Inc (BSSP) | 7775.20% |
| Omnimmune Holdings Inc (OMMH) | 7775.20% |
| Atreca Inc (BCEL) | 7775.20% |
Compared to its competitors, Endonovo Therapeutics Inc's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.